Hikal
346.05
-12.85(-3.58%)
Market Cap₹4,425.30 Cr
PE Ratio48.84
IndustryHealthcare
Company Performance:
1D-3.58%
1M-7.92%
6M-14.10%
1Y+0.06%
5Y+176.07%
View Company Insightsright
Latest news about Hikal
Hikal's Jigani Unit Passes Brazilian Anvisa GMP Audit Jun 17, 2025
Hikal Limited's Jigani facility successfully passed a Good Manufacturing Practice (GMP) audit conducted by Brazilian Anvisa, Brazil's health regulatory agency. This achievement signifies compliance with Brazilian regulatory standards and could potentially open new opportunities for Hikal in the Brazilian pharmaceutical market. The approval aligns with Hikal's strategy to strengthen its position in the global pharmaceutical supply chain and demonstrates its ability to meet international regulatory requirements.
Hikal's Jigani Facility Passes Brazilian ANVISA GMP Audit Jun 16, 2025
Hikal's Jigani Facility Faces FDA Scrutiny with 'Official Action Indicated' Classification May 26, 2025
Hikal's Jigani Facility Faces FDA Scrutiny with 'Official Action Indicated' Classification May 23, 2025
HIKAL's Q4 Results Showcase Robust Financial Growth May 14, 2025